A fluorescent imaging plate reader (FLIPR) membrane potential (V m ) assay was evaluated for pharmacological characterization and high-throughput screening (HTS) of rat glycine transporter type 2 (rGlyT 2 ) in a stable rGlyT 2 -HEK cell line. Data show that glycine activation of rGlyT 2 consistently results in a concentration-dependent V m response on the FLIPR that is blocked by the potent and selective GlyT 2 antagonist 4-benzyloxy-3,5-dimethoxy-N-[1-dimethylaminocyclopentyl)methyl]-benz-amide (Org-25543). Agonist and antagonist pharmacologies match those reported using conventional [ 3 H]glycine uptake assays and electrophysiology. The glycine response is dependent on buffer ionic composition consistent with GlyT 2 physiology. Assay signal-to-background and coefficient of variation meets sufficient statistical criteria to conduct HTS. The results of a screen of the chemical inventory demonstrate that the assay is able to successfully identify and confirm GlyT 2 inhibitors. The advantages of this assay are its homogeneity, compatibility with both 96-and 384-well formats, and lack of radioactivity usage. Thus, the authors conclude that a fluorescence-based V m assay on FLIPR is a viable approach for identification and pharmacological profiling of small molecule modulators of the electrogenic transporter rGlyT 2 . (Journal of Biomolecular Screening 2005:365-373) 
G LYCINE IS A MAJOR INHIBITORY amino acid neurotransmitter that affects synaptic transmission throughout the spinal cord and brain stem of vertebrates. 1 Activation of the strychninesensitive glycine receptor transduces its inhibitory signaling. 2 In addition, glycine modulates excitatory neurotransmission by potentiating glutamate activation of N-methyl-D-aspartate receptors. 3 Termination of glycine neurotransmission is mediated by rapid reuptake into the presynaptic terminal or surrounding glial cells that is catalyzed by sodium-and chloride-dependent glycine transporters. 4 To date, 2 separate genes that encode functional glycine transporters have been identified, GlyT 1 and GlyT 2 . 5, 6 GlyT 1 is expressed as 3 variant isoforms that arise from transcription by 2 different promoters and by alternative mRNA splicing. 7 GlyT 1 isoforms are expressed exclusively in glial cells distributed throughout the adult rat CNS. 7 GlyT 2 is expressed as 2 isoforms in rat and 3 isoforms in mice that arise from alternative mRNA splicing. 8, 9 It is distributed predominantly in neurons throughout the brain stem and spinal cord. 7 Glycine transporter expression patterns and regulation of CNS glycine levels make these proteins attractive potential therapeutic targets for a variety of disorders such as schizophrenia, spasticity, and chronic pain. [10] [11] [12] [13] The standard method used to identify small molecule inhibitors of glycine transporter activity is a [ 3 H]glycine uptake assay. [14] [15] [16] Cells expressing the transporter are treated with radiolabeled glycine in the presence or absence of inhibitors, extracellular radiolabel is washed away, cells are lysed, and radioactivity is counted. The advantages of this method are that it provides a functional readout of transporter activity and is well validated in the literature. However, drawbacks include limitations in throughput, as the assay has been described only in 96well or lower density formats; requirement for expensive radioactivity monitoring and waste disposal procedures; and lack of homogeneity. Taking advantage of the electrogenicity of glycine transporters, 17, 18 we have developed a novel, homogenous, fluorescence-based, functional high-throughput screening (HTS) assay of glycine transporter activity using the Molecular Devices fluorescent imaging plate reader (FLIPR) membrane potential (V m ) assay kit in conjunction with HEK-293 cells that recombinantly express rat GlyT 2 . Principally, GlyT 2 -HEK cells are loaded with the proprietary, Molecular Devices fluorescent V m indicator dye designed to increase or decrease in fluorescence intensity in response to depolarization or hyperpolarization of the cell membrane, respectively. The V m dye mixture also contains a cellimpermeable quencher reagent that removes nonspecific background signal due to extracellular fluorescence. After loading, cells are placed on FLIPR and exposed to glycine, in the presence or absence of compounds. Glycine activates the electrogenic GlyT 2 transporter, a net positive charge accumulates inside the cell, the membrane becomes depolarized, and a resultant increase in fluorescence intensity is read. In our characterization of this approach, we describe the critical assay development parameters, pharmacological validation, HTS assay statistics, confirmed hit rate from a screen of our chemical inventory, and IC 50 profiles of compounds identified from the Library of Pharmacologically Active Compounds (LOPAC). Collectively, these results demonstrate the validity and reliability of this assay.
MATERIALS AND METHODS

Materials
Cell culture and molecular biology reagents were purchased from Invitrogen Corporation (Carlsbad, CA) unless otherwise noted. Org-25543, 4-benzyloxy-3,5-dimethoxy-N-[1dimethylamino-cyclopentyl)methyl]-benz-amide ( Fig. 1) , was prepared at Purdue Pharma according to a published procedure. 15 All other chemicals and reagents, other than Purdue Pharma's chemical inventory, were purchased from Sigma (St. Louis, MO).
Cloning and stable rGlyT 2 -HEK cell line development
The 2.4-Kb cDNA encoding the 800-amino acid open reading frame of the rat GlyT 2a glycine transporter 6 was cloned by PCR amplification from rat spinal cord cDNA. PCR primers were designed to sequences corresponding to the 5′ (AT GGA TTG CAG TGC TCC CAA) and 3′ (GACT AGC ACT GGG TGC CCA ) ends of the rat GlyT 2a open reading frame listed in GenBank sequence L21672. PCR amplification was performed with these primers on oligo-dT-primed first strand cDNA from rat spinal cord total RNA, using high-fidelity KOD polymerase (Novagen, Madison, WI). A single 2.4-Kb product was purified and checked by restriction analysis and then cloned into pENTR-TOPO. Recombinant plasmids containing the full 2.4-Kb insert were identified by restriction analysis and sequenced on both strands to confirm the identity of the clone, as well as to identify any cloning-induced mutations. Interestingly, the consensus sequence for the GlyT 2a cDNA from our Sprague Dawley rat spinal cord cDNA demonstrated 5 nucleotide differences from the GenBank rat GlyT 2a sequence. Of these 5, 3 led to changes in the predicted protein sequence of the translated cDNA: alanine at residue 139 in L21672 to glycine in our sequence, proline at 150 to alanine in our sequence, and proline at 399 to alanine in our sequence. When the predicted amino acid sequence from our cDNA and that of the GenBank sequence were aligned with sequences from human and mouse GlyT 2 proteins, our sequence was identical to the mouse sequence at these 3 residues. In addition, our sequence was identical to the 2 human GlyT 2 variants in the database at residues 139 and 399 and was a conservative variant from the human sequences at residue 151 (human GlyT 2 and human variant GlyT 2 : val149; our rat GlyT 2a : ala151). Finally, BLAST analysis of our rat GlyT 2 cDNA sequence against the rat genomic DNA sequences in GenBank identified 100% identity between our cDNA sequences and rat chromosome 1 sequences in a presumptive exon sequence encoding amino acid residues 139 and 151. These results indicate that our cDNA likely represents the consensus rat GlyT 2 cDNA sequence.
The rGlyT 2 cDNA expression construct (5 µg) was transfected into human embryonic kidney (HEK-293) cells by lipofectamine plus reagent according to the manufacturer's instructions. Twentyfour hours later, cells were split in limiting dilution into multiple 96-well plates in selection media containing 20 µg/mL blasticidin and incubated for 3 weeks at 37°C, 5% CO 2 , and 95% humidity. Plates containing ≤1 clone per well were grown until wells positive for single clones were confluent. Individual clones were then arrayed into columns of a destination 96-well plate and partly split into 6-well plates for culture maintenance. Array plates were washed once with Tyrode's buffer (Sigma), and cells were loaded 0.5 to 1 h with FLIPR V m dye at 1× in Tyrode's according to the manufacturer's instructions (Molecular Devices, Inc., Sunnyvale, CA). Cells were then placed onto the FLIPR (FLIPR 96 , Molecular Devices, Inc.) plate reader, and fluorescence changes in response to 2.5 mM glycine in the presence or absence of 10 µM Org-25543 were measured. Approximately 15 clones were identified that reproducibly responded to glycine and were completely blocked in the presence of inhibitor. The clone with the greatest signal-tonoise (S/N), best stability of response with passage number, and best adhesion to collagen precoated plates (Becton Dickinson, Franklin Lakes, NJ) was expanded, characterized, and used for subsequent studies. The chosen clone was routinely grown and subcultured in Dulbecco's Modified Eagle Medium, 10% fetal bo- Org-25543 was synthesized as previously described, and its structure is illustrated. 15 vine serum (HyClone, Logan, UT), 100 U/mL penicillin, 100 µg/ mL streptomycin, and 20 µg/mL blasticidin growth media.
V m measurements in rGlyT 2 -HEK cells: 96-well format
Cells were seeded into collagen-precoated, black-wall, clearbottom, 96-well plates (Biocoat, Beckton Dickinson) at 75,000 cells/well in 100 µL growth media 24 h prior to assay. On the day of assay, cells were washed twice with 100 µL Tyrode's buffer or other buffers as indicated. To minimize loss of cells, these washes were carried out using a vacuum-based 8-channel Costar aspirator (Corning Life Sciences, Acton, MA). Alternative cell-washing techniques, such as automated cell washing or hand flicking, that are sufficient for parental HEK-293 cells resulted in extensive cell loss in the rGlyT 2 stable HEK-293 cell line. Cells then were loaded for 0.5 to 1 h at 37°C, 5% CO 2 with 50 µL/well FLIPR V m dye dissolved in the same buffer. After loading, cells were placed onto the stage of a FLIPR 96 . The FLIPR protocol monitored baseline fluorescence for 15 s, added 50 µL of 4× antagonist dilution, monitored fluorescence for 5 min, added 100 µL of 2× agonist, and read the fluorescence for an additional 5 min. For compound library screening, the final compound concentration was 6 µM. The final DMSO concentration was held constant at 0.3% for all experiments. The concentration 0.3% was chosen as the assay tolerates DMSO concentrations up to 0.5%. Above 0.5%, the assay signalto-background (S/B) deteriorates significantly dependent on DMSO concentration. Mock plates were prepared exactly as the compound library plates but contained only DMSO and no compounds.
V m measurements in rGlyT 2 -HEK cells: 384-well format
rGlyT 2 -HEK cell adhesion was less consistent and reproducible 24 h after seeding in collagen-precoated, black-wall, clear-bottom, 384-well plates (Biocoat, Beckton Dickinson) at cell densities ranging from 10,000 to 75,000 cells/well in 50 µL growth media. Consequently, seeding cells 1 day prior to assay led to extensive cell blow off and inconsistent data. Thus, to minimize cell loss due to washing, cells were first grown to 80% to 90% confluence in T150 cm 2 flasks. On the morning of assay, cells were seeded into collagen-precoated, black-wall, clear-bottom, 384-well plates as follows: flasks of cells were rinsed once with 10 mL Tyrode's buffer, cells were trypsinized, spun at 150g, resuspended in Tyrode's buffer, and seeded at 50,000 cells/well in a volume of 30 µL/well into 384-well plates using a multidrop dispenser (Labsystems, Farnborough, Hampshire, UK). Cells were allowed to attach for 4 to 6 h at 37°C, 5% CO 2 in Tyrode's. V m dye was loaded by addition of 10 µL 4× dye and incubated for 0.5 to 1 h at 37°C, 5% CO 2 . After loading, cells were placed onto the stage of a FLIPR 384 . The FLIPR protocol monitored baseline fluorescence for 15 s, added 10 µL of 6.7× antagonist, monitored fluorescence for 2 min, added 17 µL of 3.9× agonist, mixed twice at a volume of 20 µL, and read fluorescence for an additional 3 min. For compound library screening, the final compound concentration was 6 µM. The final DMSO concentration was held constant at 0.3% for all experiments for the same reasons as described for the 96well formatted assay. Mock plates were prepared exactly as the compound library plates but contained only DMSO and no compounds.
Data analysis
Some experiments were expressed as percentage of control. Percentage of control data that is shown is the average of multiple determinations normalized to the maximum average counts in the presence of the highest concentration of glycine in Tyrode's or control buffer and to the minimum average counts in the presence of buffer. Normalization calculations were conducted using GraphPad Prism version 3.02 software (San Diego, CA) or Microsoft Excel. Theoretical curves were generated using nonlinear regression curve-fitting analysis in GraphPad Prism version 3.02. *p < 0.05, **p < 0.01, and ***p < 0.001 values were determined by 1-way analysis of variance, followed by Bonferroni's multiple comparisons test for comparisons of 3 or more groups using GraphPad Prism version 3.02 software. p-values were determined by unpaired t-test for comparisons of 2 groups using GraphPad Prism version 3.02 software. Data analysis of 384-well HTS was performed using ActivityBase version 5.1 software (IDBS, Parsipanny, NJ). The analysis equation used to calculate percentage inhibition was (1 -(sample -min)/(max -min)) × 100, where max was the average of the positive responses to 2.5 mM glycine and min was the average of the negative control responses to 2.5 mM glycine after preaddition of 5 µM Org-25543.
RESULTS
Preliminary reports indicate that the FLIPR V m dye assay format is feasible for measurement of functional electrogenic transporter activity. This has been shown for human GAT-3, a transporter for GABA 19 and member of the superfamily of Na + /Cl --dependent transporters to which GlyT 2 also belongs. Because GlyT 2 is similarly electrogenic (Fig. 2) , 18, 20 application of the FLIPR V m dye for assay of rGlyT 2 stably expressed in HEK-293 cells was evaluated. V m dye fluorescence responses to 2.5 mM glycine in rGlyT 2 -HEK cells were tested on a FLIPR 96 plate reader and were compared to responses from untransfected HEK-293 cells (Figs. 3A, 3B). S/B responses in the 96-well format, as determined by fluorescence change (∆F) after agonist divided by ∆F after buffer, were significantly greater in stable rGlyT 2 cells than those in untransfected HEK-293 cells (rGlyT 2 mean ± SEM S/N = 8.4 ± 1.2, n = 7 plates; untransfected HEK-293 average S/N = 1.2 ± 0.2, n = 3 plates; p < 0.001). Org-25543 (5 µM) blocked the responses to glycine by 80% ± 2% (n = 5). No changes in fluorescence were observed in response to glycine when rGlyT 2 cells were loaded with the calcium indicator dye, fluo-4 (data not shown). In addition, reverse transcriptase-PCR of RNA isolated from stable rGlyT 2 -HEK cells and parental HEK-293 cells using primers specific for the rGlyT 2 sequence yielded a specific band of appropriate size in the stable rGlyT 2 -HEK cells only (data not shown).
Glycine concentration dependence of V m fluorescence responses was measured in a 96-well format (Fig. 3C ). Responses were dependent on concentration, with an EC 50 of 319 ± 55 µM (n = 5) consistent with previously reported values using conventional [ 3 H]glycine uptake assays in GlyT 2 expressing HEK-293 cells (220 µM). 17 In addition, Org-25543 concentration dependence of inhibition of V m responses to 2.5 mM glycine was evaluated ( Fig. 3D ). Inhibition was dependent on compound concentration, with an IC 50 of 31 ± 6 nM (n = 5) consistent with the literature (16 nM). 15 A distinguishing characteristic of the GlyT 2 transporter is its unique substrate specificity profile. 6,21 [ 3 H]-glycine uptake assays have shown that GlyT 2 transports glycine with high efficiency, but unlike GlyT 1 , it does not transport sarcosine. Also, GlyT 2 transport is selective against other amino acid analogues or neurotransmitter transporter substrates. Thus, we characterized the substrate specificity profile for rGlyT 2 in the FLIPR V m assay (Fig. 4) . The data show that rGlyT 2 membrane potential responses are highly selective for glycine. The GlyT 1 -selective substrate sarcosine elicits no response in this assay, consistent with literature reports. 6, 17, 21 A battery of other amino acid analogues or neurotransmitter transporter substrates also did not elicit any specific V m fluorescence responses in these cells as compared to untransfected HEK-293 controls ( Fig. 4) .
Another important physiological characteristic of the GlyT 2 transporter is its Na + and Clionic dependence. GlyT 2 requires 3 Na + and 1 Clion for every glycine molecule transported. 18 [ 3 H]glycine uptake assays have shown that glycine transport, in response to subsaturating concentrations of glycine, is significantly decreased when Na + or Clions are reduced in the assay buffer. 6, 17, 21 Thus, we tested the effect of varying buffer compositions on V m fluorescence responses to glycine. The ionic compositions of the 3 buffers tested (NaCl control, LiCl, and NaI) are described in Table 1. The V m response to 2 mM glycine is significantly inhibited when NaCl is substituted with either LiCl or NaI, to reduce Na + or Clions, respectively (Fig. 5A ). In NaCl control buffer, glycine responses are concentration dependent with an EC 50 of 303 ± 34 µM, n = 9 (Fig. 5B) . In LiCl buffer, no significant responses to glycine are observed at any concentration (Fig. 5B) . In NaI buffer, only the very highest glycine concentrations yield minimal responses, demonstrating that the glycine concentration-dependence curve appears substantially right shifted (estimated EC 50 > 3 mM; Fig. 5B ).
Using the FLIPR V m dye assay, we screened LOPAC (Sigma) in a 96-well format to determine what proportion of known, biologically active molecules exhibit nonspecific activity at GlyT 2 . The screening statistics are summarized in Table 2 . The hit cutoff was set to 70% inhibition of the response to 2.5 mM glycine. Of the 16 LOPAC plates, there were 24 active wells identified (primary hit rate = 1.9%). These wells were cherry-picked for single-point confirmation at 6 µM. Four of the 24 active wells confirmed (0.3% confirmed hit rate). The purified, crystalline form of these 4 LOPAC hits was ordered from Sigma and retested for IC 50 profiling. Three of the 4 reconfirmed.
The 3 novel GlyT 2 inhibitors that were identified from LOPAC were emodin, an inhibitor of NFκB activation 22 ; propionylpro- Buffer pH was 7.5. The 3 buffers were identical except for the specified substitutions for NaCl. All 3 buffers differed from Tyrode's in that magnesium sulfate was substituted for magnesium chloride, potassium acetate was substituted for potassium chloride, cesium bicarbonate was substituted for sodium bicarbonate, and calcium chloride concentration was reduced from 1.8 mM to 0.5 mM. The reason for these substitutions was to reduce the contribution of Na + and Cl ions coming from these inorganic salts, thereby limiting the origin of these ions to NaCl or its substitutions. Table 1 . FLIPR V m responses to 2 mM glycine were significantly inhibited in these alternate buffers. (B) Effect of buffer substitution on the glycine concentration-response curve. Glycine responses were concentration dependent in NaCl-containing control buffer, but responses to various glycine concentrations were inhibited in the substituted buffers. For both panels, data points are mean ± SEM of independent experiments as follows: n = 9 for control, n = 6 for LiCl, and n = 5 for NaI. mazine, a dopamine receptor type 2 antagonist 23 ; and tyrphostin AG 528, an epidermal growth factor receptor tyrosine kinase inhibitor. 24 Their structures are depicted in Figure 6A . The concentration dependence for inhibition of GlyT 2 was evaluated using the FLIPR V m assay (Fig. 6B) . Inhibition was dependent on compound concentration, with IC 50 values of 7.3 ± 1.8 µM (n = 3), 5.5 ± 2.0 µM (n = 3), and 1.5 ± 0.4 µM (n = 3) for emodin, proprionylpromazine, and tyrphostin AG 528, respectively.
Responses to glycine were significant and reproducible in the 384-well format as well (Figs. 7A, 7B ). In 384, S/B was calculated as max fluorescence (F max ) after glycine divided by F max after glycine in the presence of 5 µM Org-25543. The average S/B was 23 ± 2, average coefficient of variation for glycine response was 14.5% ± 0.4%, and average Z factor was 0.42 ± 0.02 for 25 mock plates tested on 15 separate occasions.
Using the GlyT 2 FLIPR-384 V m assay, HTS was conducted to identify novel small molecule inhibitors of GlyT 2 from the Purdue Pharma L.P. compound collection. Two hundred eighty compound library plates were screened in a 384-well format. The screening statistics are summarized in Table 3 . Hit cutoff was set to 70% inhibition of the response to 2.5 mM glycine. A total of 288 active wells were identified. The FLIPR trace data of each of these active wells were visually inspected. Wells that exhibited compound fluorescence of ≥20,000 counts were excluded from the hit list. Using this criterion, 141 active wells were identified (primary hit rate = 0.16%). Of these wells, 139 were cherry-picked for single-point confirmation at 6 µM. Fourteen of the 139 active wells confirmed (0.016% confirmed hit rate). One of these active wells represented Org-25543. Thus, 13 new, confirmed hits were identified.
DISCUSSION
Electrogenic transporters dependent on Na + /Clor Na + /K + gradients play a major role in the deactivation of important neurotransmitter signaling pathways such as glutamate, GABA, glycine, and the biogenic amines norephinephrine, dopamine, and serotonin. 25, 26 Deregulation of these systems leads to serious pathophysiological consequences including stroke, epilepsy, psychosis, depression, spasticity, and chronic pain. [10] [11] [12] [13] Thus, neurotransmitter transporters represent key targets for therapeutic small molecule agents that could restore normal neurotransmitter signaling and alleviate debilitating disease. Rational discovery of such compounds depends on the rapid and accurate assessment of electrogenic transporter activity.
Conventional methods for assaying transporter activity include radiolabeled substrate uptake assays or electrophysiology. Traditional radioactive uptake assays are well-validated functional readouts of transporter activity, 14, 15, 17 yet the limitations of these assays include low-density well formats such as 12-or 24-well plates, large quantities of radioactivity (>100,000 dpm/well), multiple wash steps to preequilibrate cells or remove untransported radiolabeled substrate, cell lysis to stop the reaction, and relatively long reaction times (0.25-1 h). 14, 15, 17 More recently, a scintillation proximity-based radioactive uptake assay (SPA) has been described. 27 The SPA format offers several advantages over the traditional format as it is conducted in 96-well density allowing integration with standard laboratory robotics and 96-well plate readers. Furthermore, it is homogenous and thereby adaptable for HTS. However, the SPA format retains several drawbacks, including a Note: Screen signal-to-background (S/B) = 8 ± 0.4 (mean ± SEM); screen Z′ = 0.45 ± 0.03. Ninety-six-well screening assay was performed as described in the Materials and Methods section. Positive and negative control wells were located in columns 1 and 12, the plate edges. Fluorescence count averages from middle wells of mock and screening plates were typically higher by 10% to 30%. n = 16 plates for all the statistics listed. dependence on Cytostar-T scintillating microplates (available from Amersham Biosciences, Amersham, UK). These plates are available only in a 96-well format and thus preclude the use of 384well densities. Furthermore, substantial quantities of radioactivity, similar to those used in the traditional uptake assays, and long reaction times of 2 to 3 h are required. 27 Electrophysiological assays of transporter activity take advantage of the electrogenicity of these targets. These assays record the amount of current necessary to clamp the cell membrane at a given V m in the presence or absence of transporter, substrate, or inhibitor. 17, 18, 20 Electrophysiology offers the advantage of a functional, nonradioactive readout with exquisite time resolution. For GlyT 2 , these assays are usually performed in Xenopus oocytes 18, 20 yet have also been described in recombinant HEK-293 cells. 17 In oocytes, electrophysiological measurements carried out in conjunction with [ 3 H]glycine uptake assays have allowed for the detailed characterization of the stoichiometry of glycine transporters. 18, 20 Thus, the advantages of this approach are numerous. However, electrophysiology has inherent limitations, including low throughput (1 cell is assayed at a time), a requirement for highly skilled technical personnel with specific expertise, and specialized equipment incompatible with standard laboratory robotics. In addition, the technique and equipment can vary with choice of parental cell type, in that oocyte electrophysiology uses different equipment and skills than that required for mammalian cell patch clamp methods. Although recent advances in higher throughput electrophysiology such as IonWorks (Molecular Devices, Inc.) or PatchXpress (Molecular Devices) can theoretically reduce the magnitude of these limitations, these technologies are not yet proven in practice as applicable to the assay of electrogenic transporters such as GlyT 2 .
Thus, taking advantage of the electrogenicity of GlyT 2 , a member of the Na + /Cl --dependent family of transporters, we have developed an alternative, fluorescence-based FLIPR V m assay approach to measure this transporter's activity. The assay can be performed in either 96-or 384-well formats and is homogenous, fluorescence-based, kinetic, and uses relatively short reaction times of approximately 1 to 5 min. We have shown that the assay accurately reports appropriate pharmacological profiles, substrate specificity, and ionic dependence characteristics of GlyT 2 . The signal is glycine specific, is blocked by the GlyT 2 inhibitor Org-25543 with the appropriate potency, and is both Na + and Cldependent. However, a minor portion of the signal, ≤20%, is not blocked by Org-25543. Moreover, sarcosine, a selective GlyT 1 substrate, induces a substantial signal in parental HEK-293 cells that is significantly lower in the GlyT 2 -HEK cells. It is possible that HEK-293 cells endogenously express a glycine transporter that could be 2 and Z′ = 0.64. This plate was statistically very good quality; however, some edge effect variability was observed in rows A and P and columns 1 and 24 that was often much more pronounced in other screening plates. The edge effects from the outer columns led to decreased signal-to-noise and variability that decreased the average Z′ value for the entire high-throughput screening as described in the Results section. The edge effects from the outer rows led to an increased number of false positives and a decreased confirmed hit rate as described in the Results section. (B) Columns 1, 2, 23, and 24 from the plate in panel C are overlayed. Traces show that all the wells treated with glycine responded, and the wells pretreated with inhibitor were blocked. GlyT 1 as suggested by the sarcosine response and the small portion of signal that is not blocked by Org-25543. A potent and selective GlyT 1 inhibitor, Org-24598, has been previously described. 28 Indeed, this compound would prove to be a valuable tool to mechanistically characterize the response to sarcosine in these cells. Unfortunately, the compound is not currently available commercially; thus, we were not able to test this hypothesis in our V m assay. Screening Z′ was marginal, as was the hit-confirmation rate, with respect to industry standards, probably due to relatively high variability in the negative control wells. In addition, Z′ was calculated from control wells located on the edges. The assay did have substantial edge effects in both the outer columns and rows of 96well and 384-well assays. Preliminary testing of the cell-based assay edge effect reduction technique 29 in which newly seeded plates are incubated at room temperature for 1 h prior to placing them in a 37°C incubator did not reduce this problem (data not shown). Thus, continued assay optimization to reduce edge effects or perhaps development of a more robustly expressing cell line with greater S/B to overcome variability in the negative control wells may improve the Z′ and reduce the false-positive hit rate. Nonetheless, the assay meets sufficient statistical criteria for successful HTS in 384-and 96-well formats. Confirmed hits, including several novel GlyT 2 inhibitors that originated from LOPAC, were successfully identified. Thus, we conclude that a fluorescence-based V m assay on FLIPR is a viable approach for identification and pharmacological profiling of small molecule modulators of GlyT 2 that may aid in the discovery of novel therapeutics with potential relevance to the treatment of various pathological and debilitating diseases.
